Literature DB >> 19812163

Hepatitis C virus (HCV) proteins induce NADPH oxidase 4 expression in a transforming growth factor beta-dependent manner: a new contributor to HCV-induced oxidative stress.

Howard E Boudreau1, Suzanne U Emerson, Agnieszka Korzeniowska, Meghan A Jendrysik, Thomas L Leto.   

Abstract

Viral hepatitis-induced oxidative stress accompanied by increased levels of transforming growth factor beta (TGF-beta) and hepatic fibrosis are hallmarks of hepatitis C virus (HCV) infection. The mechanisms of redox regulation in the pathogenesis of HCV-induced liver disease are not clearly understood. The results of our current studies suggest that reactive oxygen species (ROS) derived from Nox4, a member of the NADPH oxidase (Nox) family, could play a role in HCV-induced liver disease. We found that the expression of HCV (genotype 1a) cDNA constructs (full-length and subgenomic), core protein alone, viral RNA, or replicating HCV (JFH-AM2) induced Nox4 mRNA expression and ROS generation in human hepatocyte cell lines (Huh-7, Huh-7.5, HepG2, and CHL). Conversely, hepatocytes expressing Nox4 short hairpin RNA (shRNA) or an inactive dominant negative form of Nox4 showed decreased ROS production when cells were transfected with HCV. The promoters of both human and murine Nox4 were used to demonstrate transcriptional regulation of Nox4 mRNA by HCV, and a luciferase reporter tied to an approximately 2-kb promoter region of Nox4 identified HCV-responsive regulatory regions modulating the expression of Nox4. Furthermore, the human Nox4 promoter was responsive to TGF-beta1, and the HCV core-dependent induction of Nox4 was blocked by antibody against TGF-beta or the expression of dominant negative TGF-beta receptor type II. These findings identified HCV as a regulator of Nox4 gene expression and subsequent ROS production through an autocrine TGF-beta-dependent mechanism. Collectively, these data provide evidence that HCV-induced Nox4 contributes to ROS production and may be related to HCV-induced liver disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19812163      PMCID: PMC2786832          DOI: 10.1128/JVI.01059-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

Review 1.  The Nox family of NAD(P)H oxidases: host defense and beyond.

Authors:  Miklós Geiszt; Thomas L Leto
Journal:  J Biol Chem       Date:  2004-09-13       Impact factor: 5.157

2.  TLR4-NOX4-AP-1 signaling mediates lipopolysaccharide-induced CXCR6 expression in human aortic smooth muscle cells.

Authors:  Devang N Patel; Steven R Bailey; John K Gresham; David B Schuchman; James H Shelhamer; Barry J Goldstein; Brian M Foxwell; Michael B Stemerman; Jodi K Maranchie; Anthony J Valente; Srinivas Mummidi; Bysani Chandrasekar
Journal:  Biochem Biophys Res Commun       Date:  2006-07-13       Impact factor: 3.575

3.  Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis.

Authors:  Elke Ueberham; Rainer Löw; Uwe Ueberham; Kai Schönig; Hermann Bujard; Rolf Gebhardt
Journal:  Hepatology       Date:  2003-05       Impact factor: 17.425

4.  Oxidative damage, pro-inflammatory cytokines, TGF-alpha and c-myc in chronic HCV-related hepatitis and cirrhosis.

Authors:  Fabio Farinati; Romilda Cardin; Marina Bortolami; Maria Guido; Massimo Rugge
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

5.  Cutting edge: direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen species and activation of NF-kappa B.

Authors:  Hye Sun Park; Hye Young Jung; Eun Young Park; Jaesang Kim; Won Jae Lee; Yun Soo Bae
Journal:  J Immunol       Date:  2004-09-15       Impact factor: 5.422

6.  Mutational analysis reveals distinct features of the Nox4-p22 phox complex.

Authors:  Katharina von Löhneysen; Deborah Noack; Algirdas J Jesaitis; Mary C Dinauer; Ulla G Knaus
Journal:  J Biol Chem       Date:  2008-10-10       Impact factor: 5.157

7.  The NAD(P)H oxidase homolog Nox4 modulates insulin-stimulated generation of H2O2 and plays an integral role in insulin signal transduction.

Authors:  Kalyankar Mahadev; Hiroyuki Motoshima; Xiangdong Wu; Jean Marie Ruddy; Rebecca S Arnold; Guangjie Cheng; J David Lambeth; Barry J Goldstein
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

Review 8.  TGF-beta-induced epithelial to mesenchymal transition.

Authors:  Jian Xu; Samy Lamouille; Rik Derynck
Journal:  Cell Res       Date:  2009-02       Impact factor: 25.617

9.  Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein.

Authors:  Takeya Tsutsumi; Tetsuro Suzuki; Kyoji Moriya; Hiroshi Yotsuyanagi; Yoshizumi Shintani; Hajime Fujie; Yoshiharu Matsuura; Satoshi Kimura; Kazuhiko Koike; Tatsuo Miyamura
Journal:  Virology       Date:  2002-12-20       Impact factor: 3.616

10.  The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling.

Authors:  Andrew Macdonald; Katherine Crowder; Andrew Street; Christopher McCormick; Kalle Saksela; Mark Harris
Journal:  J Biol Chem       Date:  2003-03-05       Impact factor: 5.157

View more
  53 in total

1.  Nox4 involvement in TGF-beta and SMAD3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells.

Authors:  Howard E Boudreau; Benjamin W Casterline; Balazs Rada; Agnieszka Korzeniowska; Thomas L Leto
Journal:  Free Radic Biol Med       Date:  2012-06-19       Impact factor: 7.376

2.  NADPH oxidase 4 is a critical mediator in Ataxia telangiectasia disease.

Authors:  Urbain Weyemi; Christophe E Redon; Towqir Aziz; Rohini Choudhuri; Daisuke Maeda; Palak R Parekh; Michael Y Bonner; Jack L Arbiser; William M Bonner
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

Review 3.  Therapeutic potential of NADPH oxidase 1/4 inhibitors.

Authors:  G Teixeira; C Szyndralewiez; S Molango; S Carnesecchi; F Heitz; P Wiesel; J M Wood
Journal:  Br J Pharmacol       Date:  2016-07-14       Impact factor: 8.739

Review 4.  NADPH oxidases: an overview from structure to innate immunity-associated pathologies.

Authors:  Arvind Panday; Malaya K Sahoo; Diana Osorio; Sanjay Batra
Journal:  Cell Mol Immunol       Date:  2014-09-29       Impact factor: 11.530

5.  A far-upstream AP-1/Smad binding box regulates human NOX4 promoter activation by transforming growth factor-β.

Authors:  Guangxing Bai; Thomas D Hock; Naomi Logsdon; Yong Zhou; Victor J Thannickal
Journal:  Gene       Date:  2014-02-21       Impact factor: 3.688

6.  Transforming growth factor-β in stem cells and tissue homeostasis.

Authors:  Xin Xu; Liwei Zheng; Quan Yuan; Gehua Zhen; Janet L Crane; Xuedong Zhou; Xu Cao
Journal:  Bone Res       Date:  2018-01-31       Impact factor: 13.567

Review 7.  Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.

Authors:  Jinah Choi; Nicole L B Corder; Bhargav Koduru; Yiyan Wang
Journal:  Free Radic Biol Med       Date:  2014-05-06       Impact factor: 7.376

Review 8.  Role of NADPH oxidases in liver fibrosis.

Authors:  Yong-Han Paik; Jonghwa Kim; Tomonori Aoyama; Samuele De Minicis; Ramon Bataller; David A Brenner
Journal:  Antioxid Redox Signal       Date:  2014-01-24       Impact factor: 8.401

9.  HCV+ hepatocytes induce human regulatory CD4+ T cells through the production of TGF-beta.

Authors:  Caroline H T Hall; Rachel Kassel; Robert S Tacke; Young S Hahn
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

10.  Biphasic regulation of the NADPH oxidase by HGF/c-Met signaling pathway in primary mouse hepatocytes.

Authors:  Denise Clavijo-Cornejo; Cristina Enriquez-Cortina; Alberto López-Reyes; Mayra Domínguez-Pérez; Natalia Nuño; Marcela Domínguez-Meraz; Leticia Bucio; Verónica Souza; Valentina M Factor; Snorri S Thorgeirsson; María Concepción Gutiérrez-Ruiz; Luis E Gómez-Quiroz
Journal:  Biochimie       Date:  2013-01-16       Impact factor: 4.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.